To evaluate the multiplexing feasibility and assembly quality, GENEWIZ sequenced four E. coli genomes on one PacBio Sequel SMRT cell. This study proves the feasibility of multiplexing and highlights the key advantages of the PacBio Sequel platform as compared to its predecessor, the RSII. Discover the riveting results in this GENEWIZ-exclusive Tech Note!
This Tech Note highlights:
The key advantages of the PacBio Sequel platform as compared to the RSII
The cost and time involved to sequence 16 5Mb genomes by multiplexing on Sequel or non multiplexed sequencing on RSII
Feasibility, benefits and recent developments
Download Case Study
To learn more about our Whole Genome Sequencing services including long-read technology, visit our Whole Genome Sequencing page.